Drugs News and Research

RSS

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

Boehringer Ingelheim continues to be willing to provide WHO qualified generic pharmaceutical companies non assert declarations to manufacturer and export products containing the HIV/AIDS medication nevirapine to Rwanda and other defined developing countries.

20 Oct 2009

Report on new psychoneuroendocrinology service in outpatient treatment

The value of interdisciplinary expertise has not been implemented in clinical practice. Based on a longstanding teamwork between endocrinologist and psychiatrist, the Authors designed a new outpatient clinic, called Psychoneuroendocrinology (PNE) Service, that applies current principles of psychosomatic medicine, such as the assessment of interacting biological and psychosocial factors in the course of disease.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

PhRMA calls for appropriate incentives for continued biotechnology innovation

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.

20 Oct 2009

Alabama Supreme Court rules in favor of Novartis Pharmaceuticals

The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed entry of judgment in favor of NPC. NPC is pleased that the Alabama Supreme Court has found in our favor, which demonstrates that the State of Alabama's claims were unfounded.

20 Oct 2009

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

Shire Canada Inc., a division of Shire plc, announced today its voluntary cooperation to enable further royalty-free access to HIV/AIDS medicines for Rwanda as part of ongoing collaborative efforts to improve health and save lives in the developing world.

20 Oct 2009

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

20 Oct 2009

Family structure does not impact adolescents' behaviors

The conventional family has changed over the past decade. According to a new study by the Working Group on Adolescence of the Andalusian Society of Family and Community Medicine, which has been published in the Spanish journal Atenci-n Primaria, adolescents' perception of proper family functioning has little to do with the traditional nuclear structure.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

New research emphasizes benefits of exercise on brain and related disorders

Research presented today at Neuroscience 2009, the annual meeting of the Society for Neuroscience (SfN) and the world's largest source of emerging news about brain science and health, provides a better understanding of the brain, nervous system, and related disorders.

20 Oct 2009

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Mother Nature has provided the lizard with a unique ability to regrow body tissue that is damaged or torn ― if its tail is pulled off, it grows right back. She has not been quite so generous with human beings. But we might be able to come close, thanks to new research from Tel Aviv University.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Four Pharma companies underpay Medicaid rebate obligations, pay $124M to resolve allegations

Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical have entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs, the Justice Department announced today.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

Drugs News and Research

Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

Report on new psychoneuroendocrinology service in outpatient treatment

Two high blood pressure medicines effective in treating stable ischemic heart disease

PhRMA calls for appropriate incentives for continued biotechnology innovation

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

Alabama Supreme Court rules in favor of Novartis Pharmaceuticals

Shire Canada supports initiative for further access to antiretroviral medicine for Rwanda

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

Family structure does not impact adolescents' behaviors

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

New research emphasizes benefits of exercise on brain and related disorders

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Four Pharma companies underpay Medicaid rebate obligations, pay $124M to resolve allegations

UT student receives fellowship grant for pre-eclampsia research

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News